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Abstract
Few quantifiable tissue biomarkers for the diagnosis and prognosis of prostate cancer exist.
Using an unbiased, quantitative approach, this study evaluates the potential of three pro-
teins of the 40S ribosomal protein complex as putative biomarkers of malignancy in prostate
cancer. Prostate tissue arrays, constructed from 82 patient samples (245 tissue cores,
stage pT3a or pT3b), were stained for antibodies against three ribosomal proteins, RPS19,
RPS21 and RPS24. Semi-automated Ox-DAB signal quantification using ImageJ software
revealed a significant change in expression of RPS19, RPS21 and RPS24 in malignant vs
non-malignant tissue (p<0.0001). Receiver operating characteristics curves were calculated
to evaluate the potential of each protein as a biomarker of malignancy in prostate cancer.
Positive likelihood ratios for RPS19, RPS21 and RPS24 were calculated as 2.99, 4.21, and
2.56 respectively, indicating that the overexpression of the protein is correlated with the
presence of disease. Triple-labelled, quantitative, immunofluorescence (with RPS19,
RPS21 and RPS24) showed significant changes (p<0.01) in the global intersection coeffi-
cient, a measure of how often two fluorophore signals intersect, for RPS19 and RPS24 only.
No change was observed in the co-localization of any other permutations of the three pro-
teins. Our results show that RPS19, RPS21 or RPS24 are upregulated in malignant tissue
and may serve as putative biomarkers for prostate cancer.
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Introduction
Prostate cancer (CaP) is the second most diagnosed cancer in men, with an estimated 1.1 mil-
lion new cases of the disease worldwide in 2012 [1]. In the UK, over 40,000 new cases of CaP
were diagnosed in 2014 [2] and an estimated 180,890 new cases were diagnosed in the USA in
2016 [3]. In many countries the death rate from CaP is beginning to decrease [4], however,
this is largely being attributed to developments in the treatment rather than the diagnosis of
the disease. A biopsy with pathological analysis is the main modality of diagnosis of CaP, with
transrectal ultrasound-guided prostate biopsy procedures used as the current method of
obtaining a prostate tissue sample [5]. The current diagnostic modalities have drawbacks, such
as under sampling, or pathological reporting variation [6]. Gene or protein biomarkers in the
biopsy sample could assist in addressing some of these issues. We have previously used larges-
cale tissue arrays to identify proteins that are differentially expressed in non-malignant vs
malignant samples using a reproducible and quantitative approach [7, 8], rather than utilising
a subjective interpretation of immunohistochemical expression. In the current study, we have
applied the quantitative approach to a tissue array containing 245 human prostate tissue sam-
ples, gathered from 82 patients, stained for ribosomal (RPS) proteins.
Ribosomal (RPS) proteins
An increase in ribosome biogenesis is a critical feature of proliferating cells; there is also an
increase of ribosomal activity in tumorigenesis [9–11]. The 80S eukaryotic ribosome consists
of two subunits: the 60S (large subunit) and the 40S (small subunit) that comprise of both
nucleic acid and proteins. The 60S ribosome is thought to be made up of three rRNA chains
(25S, 5.8S, and 5S) and 46 protein subunits, whereas the 40S ribosome consists of 18S rRNA
and 33 protein subunits [12].
Differential expression or mutations within genes that code for ribosomal proteins are
found in malignant tumours of the prostate [13], oesophagus [14], breast [15] and brain [16].
Dysregulation of ribosomal protein mRNA expression has been seen across a range of cancer
cell lines [17]. These reports indicate a link between carcinoma and the overexpression of ribo-
somal proteins such as RPS27. There has been a limited amount of research specifically analys-
ing the relationship between ribosomal protein expression and human CaP tissue. The RPS27
protein is also known to be overexpressed in cancer cell lines [18] which led to RPS27 being
proposed as a putative biomarker for CaP [10]. Questions have also been raised about the effi-
cacy of another ribosomal protein, ribosomal protein L19 (RPL19), as a prognostic biomarker
following the discovery of differential expression in the gene encoding RPL19 in CaP [19].
Our results show ribosomal protein expression of RPS19, RPS21 and RPS24 is dysregulated
in human CaP and increased expression of RPS19 and RPS21 is seen in high Gleason grade
CaP that may provide an avenue for developing these as CaP prognostic biomarkers.
Materials and methods
Tissue array construction
Details of sample size calculation, patient selection, disease state and tissue block construction
have been previously described [7, 20, 21]. Archival, formalin-fixed tissue blocks were con-
structed using paraffin embedded radical prostatectomy samples gathered from 82 patients
between April 1994 and April 2002. All specimens had a preoperative serum PSA level of4
ng/mL and all were pathological stage pT3a or pT3b. All samples were organised into case
pairs defined by the following categories: Gleason grade, pathological stage, preoperative PSA
concentration. One patient from each pair was considered to have biochemical recurrence
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(PSA 0.2 ng/mL-1 within 2 years of surgery), the other was considered to be disease free
(undetectable PSA over 3 years after surgery). 6–8μm tissue array (TA) sections were placed
onto coated slides which were later diagnosed by a urological pathologist as either benign or
malignant (~78% diagnosed as Gleason grade 3+4 or 4+3). Clinical details were then collected
and added to a patient spreadsheet.
Ethics approval
Ethical approval of the use of human tissue for prostate cancer research was granted by the
joint University College London/University College London Hospital committees on the eth-
ics of human research. All handling of prostate tissue was carried out in compliance with the
International Committee on Harmonization of Good Clinical Practice. TA construction [7,
21] was carried out on archival pathological samples which were later immunohistochemically
stained with the approval from, and in accordance with, the University College London/Uni-
versity College London Hospital ethics committees. The ethics review board waived the need
for informed consent because archival pathological samples were used.
Immunostaining of the three RPS proteins in prostate tissue array
RPS19 (ab57643, 500ug/ml), RPS21(ab90874,500ug/ml), and RPS24 (ab102986, 250ug/ml,
Abcam, Cambridge, UK) were used in this study either individually (immunohistochemistry,
IHC-3,3-diaminobenzidine, Ox-DAB) or in combination (termed multiplex immunofluores-
cent, IF with FITC, Cy3 and Cy5 fluorophores). For negative controls, primary antibodies
were omitted or replaced with IgG matched controls (S1 Fig). RPS19 mouse IgG2b (200ug/ml,
106K4866, Sigma, Dorset, UK) and Rabbit IgG (2ug/ml, ab27472 Abcam, Cambridge) were
used with normal IgG protein concentrations as follows: RPS21 0.6ug/ml Rabbit IgG 2ug/ml,
RPS24 5ug/ml Rabbit IgG 2ug/ml and RPS19 0.5ug/ml mouse IgG2b 0.5ug/ml. Formalin
fixed, paraffin embedded, TA blocks were sectioned at 6–8μm, mounted onto Superfrost plus
slides and dried overnight at 60˚C. The following protocol was used for tissue staining using
the Bond polymer refine detection kit (DS9713, Leica Biosystems, Newcastle, UK). Antigen
retrieval was performed using Novocastra pH6 antigen retrieval buffer in a decloaking cham-
ber (Biocare, medical, Pacheco, CA, USA). Sections were heated under pressure for 5 min
and allowed to cool for 20 min before equilibrating to ambient temperature under tap water.
Alternatively, slides were subjected to the equivalent on-board antigen retrieval using Leica
Biosystems, Bond immunostaining robots (Newcastle, UK), using the 20 min ER1 protocol.
Following antigen retrieval endogenous peroxidase was blocked using peroxidase blocking
solution before incubation with primary antibody for 60 min at RT. Mouse primary (RPS19)
sections were then incubated for 15 mins with pre-polymer, followed by HRP polymer for 15
mins before visualisation using Ox-DAB with 10 min washes between incubations using Tris
buffered Saline Tween (TBST, 0.05M Tris, 0.85% NaCl, 0.5% Tween pH7.4). Finally, sections
were counterstained with Harris’s haematoxylin. Rabbit primary antibodies (RPS21, RPS24)
were stained without the use of pre-polymer as this linking reagent is not required when using
rabbit primary antibodies.
Signal quantification
Unbiased signal quantification was carried out using ImageJ software [22] to analyse the num-
ber of pixels showing expression compared with the total number of pixels in each converted
grayscale image. Quantification of Ox-DAB staining was achieved by first obtaining high reso-
lution images of each tissue core on a bright field microscope (Nikon) for particle analysis
with ImageJ, as described previously [20]; imaging tiles of the whole tissue array were also
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obtained using a Nano-zoomer (Hamamatsu) for illustrative purposes. The amount of tissue
present in each image was calculated using a sequence of macros [7, 8] to: open image, invert
image, convert image to 16bit, select a predetermined threshold selected using a random train-
ing set, convert image to mask, analyse particles (Size 0.5-Infinity, Circularity 0.00–1.00), save
then close the image. A similar macro was then constructed to measure the number of particles
expressing Ox-DAB signal in the segmented pixels. Amount of signal expressed in each core is
given as the amount of Ox-DAB signal / amount of tissue. Particle data (count, total area, aver-
age size and area fraction) was then incorporated into a Microsoft Excel spreadsheet contain-
ing all TA core data to allow tests of significance of difference between benign and malignant
cores and also different Gleason grades (RPS19 Gleason grade 5 (N = 16), grade 6 (N = 11),
grade 7 (N = 133), grade 8 (N = 8) and RPS21 grade 5 (N = 13), grade 6 (N = 8), grade 7
(N = 114), grade 8 (N = 9) and RPS24 Gleason grade 5 (N = 19), grade 6 (N = 14), grade 7
(N = 157), grade 8 (N = 10)) using the Mann Whitney U test. Malignant vs benign Mountain
plots were constructed using Origin (Microcal) software and area under the curve (AUC) was
calculated. Box plots were created in Origin software to illustrate differences in expression
between Gleason grades. Medcalc software was then used to create Receiver Operating Charac-
teristics (ROC) curves for statistical evaluation of the protein as a putative CaP biomarker.
Co-localization of three RPS proteins using immunofluorescence
staining
In addition to analysing expression of ribosomal proteins in prostate tissue, co-localization
was also calculated as it might be altered in disease. This approach has been described previ-
ously [7, 23]. Confocal images of multi-fluorophore, immunofluorescently labelled TA’s were
tested for the following antibodies and fluorophores: RPS19 (Cy3 = 559 / 567), RPS21 (FITC,
excitation/emission (nm) = 488 / 519), and RPS24 (Cy5 = 635 / 664) using the BondMax sys-
tem. Individual tissue cores were imaged on an Olympus IX81 confocal microscope with a
40x, 1.3 NA, oil objective lens and 6x digital zoom. Z-section step size was set to 0.17μm, yield-
ing approximately 18–24 z-sections depending on tissue section thickness. Deconvolution of
the “oif” images produced was obtained using Huygens Professional software (Scientific Vol-
ume Imaging) before quantifying co-localization using the Global Intersection co-localization
Coefficient (GIC). GIC can give an intuitive interpretation of the proportion of voxels contain-
ing intersecting fluorophore signal vs the number of voxels without intersecting signal. Direct
comparisons were made between each single channel image.
Results
Ox-DAB signal quantification and analysis
All RPS proteins showed a generally higher level of expression in malignant cores compared
with non-malignant cores (Fig 1). Malignant RPS19 (Fig 1A and 1G) and RPS21 (Fig 1C and
1I) showed largely epithelial expression, as did RPS24 (Fig 1E and 1K) but with the additional
observation of RPS24 expression in the nuclei (S2 Fig). Quantitative ImageJ analysis of RPS19,
RPS21, and RPS24 showed significant differences between malignant and non-malignant pro-
tein expression in CaP (p<0.0001, Mann Whitney U test). These results were incorporated
into Mountain plots (Fig 2) so that the amount of signal per amount of tissue in each core for
malignant (Red) vs non-malignant (Green) CaP tissue can be compared.
ROC curves can be used to evaluate the potential efficacy of each protein as a potential bio-
marker. If the AUC of the ROC curve is <0.5 it is implied that the substance tested would
yield no distinction between the two categories. Conversely, the closer the value for AUC is to
Ribosomal proteins in cancer
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1.0, the higher the sensitivity and specificity of the test, and there is a higher probability that
the biomarker will correctly identify the disease state of the tissue. Likelihood ratios are used to
determine the potential utility of a diagnostic test. A positive likelihood ratio (LR+) was calcu-
lated to determine if each ribosomal protein is correlated with the presence of disease. LR+ val-
ues over 1.0 suggest that the presence of the measured signal of RPS protein would be linked to
the presence of disease. ROC curves were constructed by plotting true positive rate (sensitivity)
Fig 1. Representative staining for three RPS proteins in malignant human prostate carcinoma tissue (A, C, E) vs non-malignant human tissue (B, D, F).
Human prostate tissue samples were obtained from 82 patients and a tissue array was constructed, containing 245 cores, and imaged using a Nikon DXM
1200 digital imaging system with a Nikon Diaphot at 20x magnification and standard bright-field settings. Images of each individual tissue core (3840x3072
pixels) were then used for quantification of the Ox-DAB signal using ImageJ software (see Materials and methods- Signal quantification). Binary,
segmented images (G, H, I, J, K, L) represent pixels that were positive for each representative antibody.
https://doi.org/10.1371/journal.pone.0186047.g001
Ribosomal proteins in cancer
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Fig 2. Expression analysis of Ox-DAB signal in prostate tissue. Area fraction (AF) was calculated by
dividing the amount of signal, in pixels, by the total number of pixels representing tissue per an unbiased
signal quantification protocol (see Materials and methods- Signal quantification). Each bar is representative of
the AF of a single TA core. Malignant cores are represented by red and non-malignant cores are represented
by green. A significant difference between AUC values was seen for each protein that was tested (p<0.0001).
https://doi.org/10.1371/journal.pone.0186047.g002
Ribosomal proteins in cancer
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against false positive rate (100-specificity) for RPS19, RPS21 and RPS24. Area fraction per
amount of tissue was converted to probit and fitted to a Gaussian function before incorpo-
ration into an ROC curve. LR+ values for RPS19, RPS21 and RPS24 were measured at 2.99,
4.21, and 2.56 respectively, indicating that each of the proteins tested is likely to have been
overexpressed because of the presence of disease (Fig 3).
Changes in RPS19 and RPS21 protein expression were also observed between high and low
Gleason grade CaP (Fig 4). RPS19 staining was significantly higher in Gleason grade 8 (N = 8)
than it was in both Gleason grade 5 (p = 0.007) (N = 16) and Gleason grade 6 (p = 0.028)
(N = 11). RPS21 had significant changes in protein expression for Gleason grade 5 (N = 13)
and Gleason grade 8 (N = 9) (P = 0.048). An ROC curve to illustrate the putative use of RPS19
as a marker of high Gleason grade reveals an AUC value of 0.84, which indicates that RPS19
may be a useful protein marker for prognostic purposes.
Co-localization of RPS19, RPS21 and RPS24
Co-localization analysis was used to evaluate changes in the co-expression of two proteins on a
TA core (Fig 5). The analysis revealed significant changes in the GIC of RPS19 and RPS24
(Cy3/Cy5) for malignant vs non-malignant CaP tissue (Fig 6). No significant difference was
observed between the co-localization of RPS21 and RPS19 (FITC/Cy3) or RPS21 and RPS24
(FITC/Cy5) fluorophore signals. Therefore, changes in co-localization patterns of some ribo-
somal proteins may facilitate their putative development as biomarkers.
Discussion
This is the first report describing at least three key proteins of the ribosome complex that are
overexpressed in human CaP tissue. Although sparse literature exists regarding the expression
of ribosomal genes or proteins in cancer, expression levels of genes coding for ribosomal pro-
teins show large variation across different tissues [24]. Moreover, it appears that the expression
of genes involved in ribosomal complex synthesis vary in different cancers [25], which may
increase transcription, resulting in the upregulation of a selection of RPS proteins in some can-
cers. There is no published information about the expression of ribosomal proteins in CaP.
RPS19, a component of the 40S subunit, is mutated in Diamond-Blackfan anaemia [26], a
congenital erythroid aplasia characterised by defective erythroid progenitor maturation. A
2005 study found that RPS19 is essential in the development of the 40S ribosomal subunit in
Saccharomyces cerevisiae [27]. Aside from this, very little is known about the functional role of
the protein in the human ribosome. Previous studies have shown that overexpression of rps19
mRNA is correlated with malignant potential in colorectal cancer (CRC) cell lines. Cell lines
such as SW620 and COLO205, which have a malignant pathological character, measured
higher expression levels of rps19 mRNA by northern blot analysis than cell lines associated
with a better prognosis (SW480 and COLO201) [28]. There was no analysis into whether the
expression of rps19 mRNA led to a difference in the quantity of RPS19 protein in the cell lines
tested. Therefore, the current study may have more relevance by making a post transcription
observation into the role of RPS19, with functional consequences relevant to CaP patients. We
also show that RPS19 expression is significantly raised in high Gleason grade CaP, which indi-
cates that it may be useful as a putative biomarker of prognosis in CaP.
RPS21 is also a component of the 40S subunit. Little is known about the role of the protein
in disease. Expression of RPS21 has previously been measured in prostate samples where
approximately 5% of samples exhibited overexpression of the protein (Human Protein Atlas,
accessed September 2016). We have shown that RPS21 had significantly raised levels of expres-
sion in malignant vs non-malignant CaP tissue although no changes were seen in the co-
Ribosomal proteins in cancer
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Fig 3. ROC of RPS19, RPS21, and RPS24 in prostate tissue. ROC curve to demonstrate the potential
ability of a label to differentiate between malignant and non-malignant prostate tissue. The probit function was
used for area fraction per amount of tissue for ROC analysis of RPS19, RPS21, and RPS24. The dotted line is
representative of an area under the curve of 0.5 which shows no distinction between the two classifiers (e.g.
normal vs malignant).
https://doi.org/10.1371/journal.pone.0186047.g003
Ribosomal proteins in cancer
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Fig 4. Changes in RPS protein expression with Gleason grade. Box plots were created in Origin software
to show the changes in expression of RPS19, RPS21, and RPS24, in different Gleason grades. Brackets
represent significant differences in protein expression (p<0.05). A significant change was observed between
RPS19 Gleason grades 5 and 8, and 6 and 8 (p = 0.007 and p = 0.028 respectively). A significant difference
was also observed in RPS21 Gleason grades 5 and 8 (p = 0.0488).
https://doi.org/10.1371/journal.pone.0186047.g004
Ribosomal proteins in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0186047 October 10, 2017 9 / 14
Fig 5. RPS19, RPS21, and RPS24 protein expression using immunofluorescence. Representative images of
the co-expression of RPS19 (Cy3- Red), RPS21 (FITC- Green), and RPS24 (Cy5- Blue) which was analysed in both
malignant (D, E, F) and non-malignant (A, B, C) prostate tissue. Whole tissue cores (A and D) were imaged on an
Olympus IX81 confocal system at low magnification. Intensity of fluorescent signals were optimised at the beginning
of each study to prevent oversaturation for each fluorophore. Quantification of co-localization was carried out on
Ribosomal proteins in cancer
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localization of RPS21 in relation to either RPS19 or RPS24 in CaP. Two somatic mutations
(c.62A>G and c.200_217del18) of the rps21 gene have also been previously identified in a
selection of prostate carcinoma samples from the COSMIC database (Cosmic database,
accessed September 2016).
The efficacy of RPS24 as a target for diagnosis or treatment of colon carcinoma has previ-
ously been evaluated following the discovery that rps24 knockdown in CRC cell lines (HCT116
and HT-29) reduced cell proliferation and hindered cell migration rate [29]. The study went
on to conclude that the rps24 gene may have a critical role in colon cancer. This raises the ques-
tion whether RPS24 is also a critical protein in the proliferation and/or migration of CaP cells.
This notion is supported by the finding in our study that RPS24 is upregulated in CaP. We
have also shown significant changes in the co-localization of RPS24 in relation to RPS19 in
images gathered from a randomly selected area of the tissue core using a 40x objective zoom (E is malignant and B
is non-malignant) on an Olympus IX81 confocal system. The image was further magnified using a 6x digital zoom.
Each image was then deconvolved (C and F) and the GIC was calculated using Huygens software (see Materials
and methods). Scale bar = 10 μm.
https://doi.org/10.1371/journal.pone.0186047.g005
Fig 6. Box plots of co-localization of RPS proteins. Global intersection coefficient (GIC) was calculated using
deconvolved, high magnification, fluorescent images (represented in Fig 5) using Huygens software (see Materials and
methods). Box plots of GIC were created for comparison between malignant (red bordered bars) and non-malignant (green
bordered bars) co-localization for RPS21/RPS19 (green/red bars), RPS21/RPS24 (green/blue bars), and RPS19/RPS24
(red/blue bars). Significance of the difference in GIC values for malignant vs non-malignant prostate tissue was calculated
using the Mann Whitney U test (* = p<0.01).
https://doi.org/10.1371/journal.pone.0186047.g006
Ribosomal proteins in cancer
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CaP which may further support the use of the protein as a putative biomarker. The rps24 gene
has been analysed and published in the Cosmic database, where one somatic mutation in CaP
(c.30A>G) from 1306 samples has been identified (COSMIC database, accessed September
2016).
In the current study, we have concluded from quantitative analysis of CaP tissue that a
cohort of three ribosomal proteins (RPS19, RPS21 and RPS24) are significantly upregulated in
CaP. Furthermore, we have shown that two of these proteins, RPS19 and RPS24 have signifi-
cant changes in their co-localization patterns in malignant vs non-malignant tissue. Our data
suggests that the use of a quantitative approach of measuring protein expression in tissue
alongside co-localization analysis with immunofluorescence staining could potentially prove
useful in the diagnosis and/or prognosis of CaP.
Supporting information
S1 Fig. Specificity controls. Antibody specificity controls showing representative human
prostate tissue stained using Mouse IgG2b at 0.5ug/ml or Rabbit IgG at 2ug/ml and representa-
tive images of prostate tissue sections stained following omission of primary antibody used as
negative controls to determine background signal. Scale bar 250μm.
(TIF)
S2 Fig. Nuclear staining of RPS24. TA slides containing non-malignant (A, B and C) and
malignant (E, F and G) CaP tissue cores were stained for RPS24 using an Ox-DAB staining
protocol and imaged using a Nano-zoomer (Hamamatsu) slide scanner at 40x magnification.
Nuclear staining can be seen in images of both non-malignant (B and C) and malignant (F and
G) CaP. Scale bar = 25μm.
(TIF)
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